Alerts will be sent to your verified email
Verify Email
THYROCARE
|
Thyrocare Tech.
|
Medplus Health Servi
|
Krsnaa Diagnostics
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Diagnostics
|
|||
|
Number of Daily Patients - Diagnostic Centres
|
42.19 Ths | n/a | 11.67 Ths |
|
Number of Samples - Quarterly
|
5.58 Million | n/a | n/a |
|
No of Tests - Quarterly
|
35.25 Mn | n/a | 5.42 Mn |
|
Financials
|
|||
|
5 yr Average ROE
|
23.13 % | 5.12 % | 32.72 % |
|
5yr average Equity Multiplier
|
1.36 | 2.1 | 1.71 |
|
5yr Average Asset Turnover Ratio
|
0.81 | 2.11 | 0.57 |
|
5yr Avg Net Profit Margin
|
21.31 % | 1.34 % | 24.81 % |
|
Price to Book
|
6.71 | 5.44 | 2.45 |
|
P/E
|
49.77 | 141.29 | 32.4 |
|
5yr Avg Cash Conversion Cycle
|
34.58 Days | 55.87 Days | -281.13 Days |
|
Inventory Days
|
16.27 Days | 73.69 Days | 8.61 Days |
|
Days Receivable
|
61.79 Days | 0.58 Days | 49.07 Days |
|
Days Payable
|
42.25 Days | 27.74 Days | 358.5 Days |
|
5yr Average Interest Coverage Ratio
|
114.35 | 2.24 | 9.83 |
|
5yr Avg ROCE
|
30.71 % | 11.02 % | 33.72 % |
|
5yr Avg Operating Profit Margin
|
37.85 % | 6.4 % | 50.58 % |
|
5 yr average Debt to Equity
|
0.0 | 0.16 | 0.37 |
|
5yr CAGR Net Profit
|
-5.02 % | 18.95 % | -19.6 % |
|
5yr Average Return on Assets
|
17.28 % | 2.55 % | 15.0 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
71.11 % | 40.39 % | 27.03 % |
|
Share Pledged by Promoters
|
100.0 % | 54.17 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
4.97 % | -0.04 % | -0.35 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
8.08 % | 1.33 % | 1.44 % |
|
Thyrocare Tech.
|
Medplus Health Servi
|
Krsnaa Diagnostics
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Distribution Channel
|
Distribution Channel
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
|
Capex
|
Capex
|
Capex
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
